Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium

Comparative Performance With Standard Dose in Prostate Cancer Diagnosis

He, Dianning MS*†; Chatterjee, Aritrick PhD; Fan, Xiaobing PhD; Wang, Shiyang PhD; Eggener, Scott MD; Yousuf, Ambereen MBBS; Antic, Tatjana MD§; Oto, Aytekin MD, MBA; Karczmar, Gregory S. PhD

doi: 10.1097/RLI.0000000000000466
Original Articles

Objectives This study investigates whether administration of low doses of gadolinium-based contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low- and high-dose injection as a new diagnostic marker.

Materials and Methods Patients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α).

Results Both low- and standard-dose DCE-MRI showed similar sensitivity (13/26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s−1) but not for standard (4.27 ± 2.20 vs 3.35 ± 1.48 s−1) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the “saturation effect”) can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA.

Conclusions These preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.

From the *Sino-Dutch Biomedical and Information Engineering School, Northeastern University, Shenyang, China; and Departments of


Urology, and

§Pathology, The University of Chicago, Illinois.

Received for publication December 7, 2017; and accepted for publication, after revision, February 10, 2018.

Dianning He and Aritrick Chatterjee share first authorship and contributed equally to this work.

Conflicts of interest and sources of funding: This work was supported by Philips Healthcare and National Institutes of Health (NIH R01 CA172801, NIH 1S10OD018448-01, NIH R01CA218700, 5 P30 CA014599-36 and the University of Chicago Institute of Translational Medicine).

Correspondence to: Gregory S. Karczmar, PhD, Department of Radiology, The University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637. E-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.